GAD65 Autoantibody Responses in Japanese Latent Autoimmune Diabetes in Adult Patients by Maruyama, Taro et al.
GAD65 Autoantibody Responses in
Japanese Latent Autoimmune Diabetes in
Adult Patients
TARO MARUYAMA, MD, PHD
1
SHILPA OAK, PHD
2 AKIRA SHIMADA, MD, PHD
3
CHRISTIANE S. HAMPE, PHD
2
OBJECTIVE — To determine whether development of insulin requirement in patients with
latent autoimmune diabetes in adults (LADA) is accompanied with the emergence of a type 1
diabetes–like autoimmune response.
RESEARCH DESIGN AND METHODS — We correlated -cell–speciﬁc autoimmunity
reﬂected in autoantibodies to the 65-kDa isoform of GAD (GAD65) with insulin requirement.
We determined GAD65Ab epitope speciﬁcities in type 1 diabetic patients, LADA patients with-
out insulin requirement (nonprogressed), and LADA patients that had developed insulin re-
quirement (progressed).
RESULTS — Recognition of a type 1 diabetes–speciﬁc GAD65Ab epitope was more pro-
nouncedintype1diabeticpatientsthaninnonprogressed(P0.001)orprogressed(P0.01)
LADApatients,withnosigniﬁcantdifferencesbetweenthetwoLADAcohorts.Thesedifferences
were particularly pronounced in samples with GAD65Ab titers 1,000 units/ml, with no dif-
ferencesinepitopespeciﬁcitiesinsampleswithhigherGAD65Abtiters.Diseaseduration(initial
diabetes diagnosis until sample collection or development of insulin requirement) in nonpro-
gressed and progressed LADA patients, respectively, was not correlated with epitope speciﬁcity,
suggesting lack of epitope maturation. This was supported by epitope analyses of longitudinal
samples from LADA patients during progression to insulin requirement.
CONCLUSIONS — First, the GAD65Ab-speciﬁc autoimmune reaction in type 1 diabetic
patients with low and moderate GAD65Ab titers differs from that in LADA patients, irrespective
of insulin requirement. Second, the GAD65Ab-speciﬁc autoimmune response in LADA patients
doesnotchangeaftertheirinitialdiabetesdiagnosis.Finally,LADApatientswithhighGAD65Ab
titers resemble type 1 diabetic patients in their GAD65Ab epitope speciﬁcity.
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L
atent autoimmune diabetes in adults
(LADA) consists of a subgroup
(10%)ofadultpatientsinitiallydi-
agnosed with type 2 diabetes, who show
signs of -cell autoimmunity and eventu-
ally develop insulin requirement (1,2).
Signs of -cell autoimmunity, such as the
well-characterized insulin autoantibod-
ies, glutamate decarboxylase (GAD65),
and the tyrosine phosphatase–like pro-
tein insulinoma-associated protein-2, in-
dicate signiﬁcant damage of the -cells
and subsequent development of insulin
requirement in these patients (1). While
autoantibodies to insulin and insuli-
noma-associated protein-2 antibody (Ab)
are inversely correlated with age at onset,
GAD65Ab shows no, and in some studies
evenapositive,correlationwithageaton-
set and is therefore a particularly attrac-
tive marker for autoimmune diabetes in
the adult population (3,4). Moreover,
GAD65Ab can be detected years after the
clinical onset of the disease, indicating
that these autoantibodies may be perma-
nent markers for the autoimmune re-
sponse (5,6).
Notably, not all LADA patients
progress to insulin requirement, raising
the possibility that the autoimmune re-
sponse in these patients resembles that
in autoantibody-positive healthy indi-
viduals, with no signiﬁcant risk for de-
velopment of insulin requirement (7,8).
A better understanding of the autoim-
mune response is necessary to predict
insulin requirement in LADA patients,
whichisimportanttopreventescalation
of blood glucose levels and subsequent
complications.
In previous studies, we have investi-
gated the humoral immune response to-
ward GAD65 as a reﬂection of islet cell
destruction (9). It remains unclear
whether the autoimmune response in
LADA patients and type 1 diabetic pa-
tientsdiffersorwhetheronlytheduration
of the prodomal period distinguishes be-
tween the two groups (10). Therefore, we
compared the GAD65-speciﬁc humoral
autoimmune response in type 1 diabetic
patients with that in LADA patients who






patients were collected at the Saitama So-
cial Insurance Hospital, Urawa City, Ja-
pan(n119).Alltype1diabeticpatients
required insulin treatment at the time of
diabetes diagnosis. Sera were collected
between 1989 and 2005 and were taken
at various times after onset of disease
(0–27yearsofdiseaseduration[median1
year]).
Patients classiﬁed as LADA patients
were admitted to the Saitama Social In-
surance Hospital, Urawa City, Japan. Di-
agnosis of LADA was made according to
thecommissionofImmunologyofDiabe-
tes Society (2) (patients were diagnosed
with type 2 diabetes and tested positive
for GAD65Ab with an onset age 30
years). None of these patients required
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after the initial diagnosis.
We differentiated two groups of
LADA patients, based on their insulin re-
quirements. Nonprogressed LADA pa-
tients (n  56) did not require insulin
treatment for over 5 years after diagnosis
with type 2 diabetes. Six of these samples
werecollectedatKeioUniversity.Someof
the samples were taken earlier (see Table
1); however, all patients were followed to
ensure that they did not require insulin
treatment for over 5 years past type 2 di-
abetes diagnosis. Progressed LADA pa-
tients (n  58) developed insulin
requirement after the initial LADA classi-
ﬁcation and had low fasting serum C-
peptide levels (0.4 ng/ml). Insulin
treatment was started at an A1C of 8%
despite usage of the maximum dose of
glibenclamide(5mg)andobservationofa
strict diet.
Longitudinal samples were obtained
from nine individuals (ﬁve male subjects,
median age 34 years) who were classiﬁed
as LADA patients and developed insulin
requirement during follow-up. Local in-
stitutional ethics committee approval was
obtained before collection of all serum
samples. Informed consent was obtained
from all patients or their legal guardians.
Theageatonsetofdiabetes(type1ortype
2), GAD65Ab titer, duration of diabetes,
requirement of insulin, and other clinical






mic, Tokyo, Japan) and the manufactur-
er’s suggested cutoff level of 1.5 units/ml.
GAD65Abpositivitywasconﬁrmedusing
a radioligand binding assay (RBA) (de-
scribed below). The World Health Orga-
nization standard for GAD65Ab (11) and
negative samples were included in every
assay to correct for interassay variation
and to express immunoglobulin binding
levels as units per milliliter (units/ml).
Cutoff levels for positivity (34 units/ml)
were calculated as the 98th percentile
from a healthy control group (n  50).
Samples with a GAD65Ab 1,000
units/ml in the initial screen were diluted
to determine their half-maximal binding
concentration. Subsequent epitope map-
ping experiments were carried out at this
half-maximal binding concentration. In
the Diabetes Antibody Standardization
Program 2005 workshop, the GAD65Ab
analysis ranked at 80% sensitivity and
91% speciﬁcity.
Recombinant Fab used in this study
Monoclonal antibodies used in this study
werepreviouslydescribed(12).Recombi-
nant Fabs (rFabs) were produced in Esch-
erichia coli 25F2 cells as previously
described(9).Brieﬂy,DPAandDPDwere
derivedfromatype1diabeticpatientand
recognize epitopes located at amino acids
483–499 plus 556–586 and 96–173, re-
spectively. Monoclonal antibody b96.11,
derived from a patient with autoimmune
polyendocrine syndrome type 2, recog-
nizes a conformational epitope involving
amino acids located in both the middle
and the C-terminus of the molecule (13).
Monoclonal antibody MICA-3, isolated
from a patient with type 1 diabetes, rec-





produced in an in vitro–coupled tran-
scription/translation system with SP6
RNA polymerase and nuclease-treated
rabbit reticulocyte lysate (Promega,
Madison, WI) as described previously
(14). The in vitro–translated [
35S]-
antigen was kept at 70°C and used
within 2 weeks.
The capacity of the rFab to inhibit
GAD65 binding by human serum
GAD65Ab was tested in a competitive
epitope-speciﬁc RBA using protein A
Sepharose (Zymed Laboratories) as de-
scribed (9). The rFab were added at a
concentration sufﬁcient to compete
binding of the originating intact mAb to
GAD65 by at least 80% (0.7–1 g/ml).
The background competition for each
rFab was established in competition ex-
periments with normal control sera.
The background was subtracted before
calculation of percent binding. The cut-
off for speciﬁc competition was deter-
mined as 10% by using a negative
control rFab D1.3 (a kind gift from Dr.
J. Foote, Arrowsmith Technologies, Se-
attle), speciﬁc to an irrelevant target,
hen-egg lysozyme, at 5 g/ml.
Statistical analyses
Binding of GAD65Ab to GAD65 in the
presence of rFab was expressed as fol-
lows: counts per minute of
[35]S-GAD65
bound in the presence of rFab/counts per
minute of [
35S]-GAD65 bound in the ab-
sence of rFab  100.
All samples were analyzed in tripli-
cate determinations, and the intra-assay
average coefﬁcient of variation was 5%
(range13–0.04).Medianages,GAD65Ab
titers, and competition levels between
groups were analyzed using the nonpara-
metric ANOVA (Kruskal-Wallis) fol-
lowed by Dunn’s multiple comparisons
test. Competition levels within each
group were tested for signiﬁcance using
the nonparametric Wilcoxon matched-
pair test. A P value 0.05 was considered
signiﬁcant.
RESULTS
Autoantibody status and clinical
parameters
The type 1 diabetic cohort had a signiﬁ-
cantly lower median age compared with
the nonprogressed and progressed LADA
patients (P  0.0001) (Table 1). No sig-
niﬁcant difference between the median
ages of the nonprogressed LADA patients
and the progressed LADA patients was
observed. We emphasize that samples
from progressed LADA patients were
Table 1—Patient characteristics










Type 1 diabetes 26 (6–84) 489 (52–4,668) 1 (0–12) NA 114 (61 female)
Nonprogressed LADA 49 (32–78) 176 (54–129,334) 7 (0.5–27) NA 56 (35 female)
Progressed LADA 45 (30–67) 657 (55–150,990) 7 (0.5–26) 2 (0–18) 58 (27 female)
Data are median (range), unless otherwise indicated. NA, not applicable.
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quirement. No signiﬁcant differences in
GAD65Ab levels between the three
groups were observed.
GAD65Ab response in relation to
insulin requirement
All serum samples were analyzed for their
binding to GAD65 in the presence of
GAD65-speciﬁc rFab DPA, b96.11, DPD,
and MICA-3 (Fig. 1). We observed signif-
icant reduction in median binding to
GAD65 in the presence of rFab DPA,
DPD, b96.11, and MICA-3 in all groups.
No correlation between GAD65Ab titer
and reduction of binding conferred by
anyoftherFabwasobservedinthetype1
diabetic and progressed LADA patients.
In the nonprogressed LADA patients, we
observed a signiﬁcant correlation of
GAD65Ab titer and reduction of binding
conferred by rFab b96.11 (P  0.005)
and DPD (P  0.004) (data not shown).
No correlation between GAD65Ab
epitope speciﬁcity and sex or age was ob-
served in any of the groups.
To determine whether the epitope
recognition differed between the
groups, we compared the differences in
reduction in median binding to GAD65
conferred by the different rFab (Fig. 1).
We found that the reduction in binding
conferred by rFab b96.11 was signiﬁ-
cantly more pronounced in type 1
diabetic patients as compared with pro-
gressed and nonprogressed LADA pa-
tients (P  0.01 and P  0.001,
respectively).
GAD65Ab response in relation to
GAD65Ab titer
Based on our above ﬁndings of a correla-
tion between GAD65Ab titer and epitope
recognition in the nonprogressed LADA
patients and our previous observation
that high GAD65Ab titers predict pro-
gression to insulin requirement (15), we
divided the analysis between samples
with GAD65Ab titers  and 1,000
units/ml(Fig.1,inset).Wefoundthatsera
exhibitinghighGAD65Abtitersamplesin
both LADA groups showed strong inhibi-
tion of GAD65 binding by rFab b96.11,
Figure 1—GAD65Ab epitope speciﬁcities in patients with different forms of
autoimmune diabetes. Sera of type 1 diabetic patients, progressed LADA, and
nonprogressed LADA patients were analyzed for their capacity of binding to
GAD65 in the presence of the indicated rFab. Results are presented as binding to
GAD65 in the presence of rFab related to uncompeted binding (set at 100%).
Median, interquartile range, and upper and lower extremes are shown. P values
are indicated. Inset: GAD65Ab epitope speciﬁcities in LADA patients with high
GAD65Abtitersresemblethoseintype1diabeticpatients.Serumsamplesoftype
1 diabetic, progressed LADA, and nonprogressed LADA patients with GAD65Ab
titers 1,000 units/ml (left panel) and GAD65Ab titers 1,000 units/ml (right
panel)wereanalyzedfortheirbindingtoGAD65inthepresenceofrFabb96.11.
Results are presented as binding to GAD65 in the presence of rFab related to
uncompeted binding (set as 100%). Median, interquartile range, and upper and
lower extremes are shown. P values are indicated.
GAD65Ab epitope speciﬁcity distinguishes LADA
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obtained from type 1 diabetic patients.
For both insulin-requiring patient groups
(type 1 diabetes and progressed LADA),
no signiﬁcant differences in inhibition
levels observed in the presence of rFab
b96.11 were observed when comparing
sera with high and low GAD65Ab titers.
However, in nonprogressed LADA pa-
tients, binding levels in the presence of
rFab b96.11 in sera with high GAD65Ab
titers were signiﬁcantly lower compared
with sera with low GAD65Ab titers (P 
0.001). Consequently, samples with
GAD65Abtitersbelowthe1,000units/ml
cutoff showed signiﬁcant differences in
the GAD65 binding in the presence of
rFab b96.11 between type 1 diabetic pa-
tientsandprogressed(P0.01)andnon-
progressed LADA patients (P  0.001).
GAD65Ab response in relation to
disease duration
We tested whether the GAD65Ab epitope
speciﬁcities may change longitudinally
toward progression to insulin require-
ment. Therefore, we correlated epitope
speciﬁcities with disease duration (initial
diabetes diagnosis) in nonprogressed
LADA patients and time from initial dia-
betes diagnosis to insulin requirement in
progressedLADApatients.Nocorrelation
withGAD65AbtiterorGAD65Abepitope
speciﬁcity was observed, indicating no
longitudinal changes over time. Longitu-
dinal samples obtained from LADA pa-
tients (n  9) during their progression to
insulin requirement were analyzed for
their epitope speciﬁcities (Fig. 2). While
some patients showed longitudinal
changes over time (Fig. 2A–C), no overall
trendinthechangeofepitopespeciﬁcities
was obvious.
rFab concentration needed for
maximal inhibition is identical in
the three groups
Disparities in inhibition levels of GAD65
bindingexertedbyarFabcouldbecaused
by different afﬁnities, or differences in
binding speciﬁcities. Therefore we estab-
lishedtherFabb96.11concentrationnec-
essarytoachievemaximalinhibitioninall
three groups (Fig. 3). The median rFab
concentration to reach 50% inhibition
(EC50) was 0.39 nmol/l for all three
groups. Serum samples whose GAD65
binding was not inhibited by rFab con-
centrations of 2.5 nmol/l, were also not
inhibited at 12.5 nmol/l rFab. This con-
ﬁrms that the assay conditions are opti-
Figure 2— No overall longitudinal trend in GAD65Ab epitope speciﬁcities suggests lack of epitope maturation. GAD65Ab epitope speciﬁcity was
analyzedinlongitudinalsamplesfromLADApatientswhoprogressedtoinsulinrequirementinthefollow-upperiod.Longitudinalsamplesobtained
from LADA patients (n  9) were analyzed for their GAD65Ab epitope speciﬁcities. GAD65 binding in the presence of rFab DPA (E), b96.11 (Œ),
and MICA-3 ( ) is reported in relation to uncompeted binding (set as 100%). The zero time point indicates time of insulin requirement, negative
values refer to time before insulin requirement, and positive values to samples obtained after initiation of insulin requirement.
Maruyama and Associates
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nmol/l) exceeded the rFab concentration
necessary to achieve maximal competi-
tion. These results also suggest that the
observed differences between the groups
were not caused by different binding ca-
pacities to the GAD65Ab epitope deﬁned
by b96.11.
CONCLUSIONS — Our results con-
ﬁrmed previous observations of different
GAD65-speciﬁc humoral immune re-
sponses in type 1 diabetic patients and
nonprogressed LADA patients (9,16).
Progressed LADA patients exhibited a
GAD65Ab epitope pattern intermediate
betweentype1diabeticpatientsandnon-
progressed LADA patients. This may in-
dicate that the GAD65Ab response
matures in patients as they progress to-
ward insulin requirement. We tested this
possibilitybyanalyzinglongitudinalsam-
plesobtainedfromasmallgroupofLADA
patients during their development of in-
sulin requirement. While some of the pa-
tients showed changes in their epitope
binding speciﬁcities, no overall trend was
observed.
In the progressed LADA patients the
disease duration before insulin require-
ment varies from 0.5 to 27 years. We an-
alyzed whether LADA patients who
progressed faster to disease showed dif-
ferent GAD65Ab epitope speciﬁcities
from patients that progressed slower.
However, no correlation between
GAD65Abepitopespeciﬁcitiesandlength
of the prodomal period was observed.
These ﬁndings together with our earlier
observations of longitudinal changes in
GAD65Ab epitope speciﬁcities in healthy
adultindividualsduringtheirprogression
totype2diabetes(17)leadtoourhypoth-
esis that the autoimmune response in
LADA patients remains constant after
type 2 diabetes onset.
SomeofthenonprogressedLADApa-
tientsshowedaverylongdiseaseduration
without developing insulin requirement
(up to 27 years since initial diabetes diag-
nosis). While the presence of GAD65Ab
in LADA patients is considered as a risk
factorforsubsequentinsulinrequirement
(1),oneautoantibodyaloneconfersonlya
low risk for progression in the general
population (7). One could therefore as-
sume that some LADA patients show
signs of -cell autoimmunity but are un-
likely to develop insulin requirement. To
test this hypothesis, we analyzed
GAD65Ab epitope speciﬁcities in correla-





interquartile range, and upper and lower extremes are shown.
GAD65Ab epitope speciﬁcity distinguishes LADA
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epitope speciﬁcity was observed. These
data are in agreement with the longitudi-
nal study of LADA patients in the U.K.
Prospective Diabetes Study 77, reporting
stagnant GAD65Ab epitope reactivities
(18).
The observed differences in GAD65Ab
epitope speciﬁcities were particularly
pronounced in the samples with medium
to low GAD65Ab titers, while high
GAD65Ab titer samples in the three
groups recognized the type 1 diabetes–
associated b96.11 epitope to similar de-
grees. This may indicate that the type 1
diabetes–associated autoimmune re-
sponse is more emphasized in LADA pa-
tients with high GAD65Ab titers. While
theseunexpectedﬁndingsneedtobecon-
ﬁrmed in a larger study cohort, previous
studies (15,19) report that LADA patients
with high GAD65Ab titers progress to in-
sulin requirement more often than LADA
patients with low GAD65Ab titers. More-
over, a recent study (20) reported that
LADA patients with high GAD65Ab titers
resemble type 1 diabetic patients with re-
spect to clinical characteristics, genetic
susceptibility, and other autoimmune
components.However,nocorrelationbe-
tween GAD65Ab titer and aggressiveness
of -cell autoimmunity was found in the
recent U.K. Prospective Diabetes Study
77 (18). These differences may be caused
by different distribution of GAD65Ab ti-
ters,asourLADAcohortsincludedserum
samples with very high GAD65Ab titers,
while the sera in the U.K. Prospective Di-
abetes Study 77 cohort showed more
moderate GAD65Ab titers.
The observed differences in
GAD65Ab epitope speciﬁcities between
high and low GAD65Ab titer samples
within the nonprogressed LADA patients
suggest a heterogeneous autoimmune re-
sponseinthisgroup.Thediseaseprogres-
sion in high titer LADA patients with type
1 diabetes–like GAD65Ab epitope speci-
ﬁcity needs to be analyzed in future stud-
ies to address this hypothesis.
We conclude that the autoimmune
responses in LADA and type 1 diabetic
patients show different GAD65-speciﬁc
immune responses, particularly in the
samples with moderate GAD65Ab titers.
The particular GAD65Ab characteristics
remain stable and do not mature during
progression to insulin requirement,
whichmaysuggestadistinctautoimmune
response in the pathogenesis for LADA
patients.
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